This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background:Mid-ventricular obstruction (MVO) is a rare subtype of hypertrophic cardiomyopathy (HCM) , but it is associated with severe symptoms and worse clinical outcomes. Circulation, Volume 150, Issue Suppl_1 , Page A4139929-A4139929, November 12, 2024. Whereas the mechanisms of MVO has not fully elucidated.
Female patients showed a lower prevalence rate of pre-existing coronary artery disease (48% vs. 75%, p < 0.001) and cardiomyopathy (17% vs. 34%, p = 0.01) compared with the male patients, while the mean age and prevalence rate of other cardiovascular risk factors were balanced.
Patients with increasing obesity have higher right- and left-sided ventricular filling pressures, increased cardiac output (CO), lower 6-min walk distance (6MWD) and worse Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. of patients had BMI ≥30 kg/m 2. Strain measurements in all four chambers were maintained as BMI increased.
I quickly reviewed the patient’s records and saw that she was a 53 year old woman with a history of BMI 40, but no other identifiable risk factors for coronary artery disease. Of course, stress cardiomyopathy is a diagnosis of exclusion. Stress cardiomyopathy can be a very convincing mimic for OMI, particularly LAD OMI.
BMI, body mass index; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. In addition, dapagliflozin was safe and well-tolerated, irrespective of COPD status.
Primary endpoints: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5, n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content